DLCI-1 is an orally available potent and selective inhibitor of cytochrome P450 2A6 (CYP2A6) that significantly decreases nicotine self-administration in both male and female mice.
orally available potent and selective inhibitor of CYP2A6 that significantly decreases nicotine self-administration mice
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
The Journal of pharmacology and experimental therapeutics, 372(1), 21-29 (2019-10-20)
During tobacco and e-cigarette use, nicotine is mainly metabolized in the human liver by cytochrome P450 2A6 (CYP2A6). Given that a slower CYP2A6 metabolism has been associated with less vulnerability to develop nicotine dependence, the current studies sought to validate
Journal of medicinal chemistry, 61(16), 7065-7086 (2018-07-12)
Cigarette smoking causes nearly one in every five deaths in the United States. The development of a specific inhibitor of cytochrome P450 2A6 (CYP2A6), the major nicotine-metabolizing enzyme in humans, which could be prescribed for the cessation of cigarette smoking
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
